Early virus clearance of SARS-CoV-2 among co-infection with malaria
BACKGROUND AND OBJECTIVES: India has witnessed significant number of cases of co-infection of malaria or dengue with COVID-19, especially during the monsoon season. It has been speculated that anti-malarial immunity might have a protective role in co-infection. Retrospective analysis of co-infection of vector-borne diseases with COVID-19 was done for comparing their remission with matched controls with COVID-19 by means of epidemiological data.
METHODS: Medical case records of patients with co-infection of malaria or dengue with COVID-19 admitted at TNMC and BYL Nair Charitable Hospital from 1 March 2020 to 31 October 2020 were analyzed retrospectively. Out of 91 cases of co-infection of SARS-CoV-2 infection with vector-borne diseases, virus clearance (VC) analysis was done for 61 co-infections with malaria.
RESULTS: Median duration of VC for co-infection with malaria was 8 days whereas, it was 12 days for controls with COVID-19 (p=0.056). Young patients (≤50 years) with co-infection recovered faster than controls age (p=0.018).
INTERPRETATION & CONCLUSION: Co-infection with malaria is associated with less severe disease and early recovery in the form of early VC. Genetic and immunological studies are necessary to confirm malaria protection against SARS-CoV-2 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Journal of vector borne diseases - 60(2023), 2 vom: 01. Apr., Seite 211-214 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rathi, Pravin M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 10.07.2023 Date Revised 18.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4103/0972-9062.364758 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359182674 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359182674 | ||
| 003 | DE-627 | ||
| 005 | 20231226080330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/0972-9062.364758 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359182674 | ||
| 035 | |a (NLM)37417172 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rathi, Pravin M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early virus clearance of SARS-CoV-2 among co-infection with malaria |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND AND OBJECTIVES: India has witnessed significant number of cases of co-infection of malaria or dengue with COVID-19, especially during the monsoon season. It has been speculated that anti-malarial immunity might have a protective role in co-infection. Retrospective analysis of co-infection of vector-borne diseases with COVID-19 was done for comparing their remission with matched controls with COVID-19 by means of epidemiological data | ||
| 520 | |a METHODS: Medical case records of patients with co-infection of malaria or dengue with COVID-19 admitted at TNMC and BYL Nair Charitable Hospital from 1 March 2020 to 31 October 2020 were analyzed retrospectively. Out of 91 cases of co-infection of SARS-CoV-2 infection with vector-borne diseases, virus clearance (VC) analysis was done for 61 co-infections with malaria | ||
| 520 | |a RESULTS: Median duration of VC for co-infection with malaria was 8 days whereas, it was 12 days for controls with COVID-19 (p=0.056). Young patients (≤50 years) with co-infection recovered faster than controls age (p=0.018) | ||
| 520 | |a INTERPRETATION & CONCLUSION: Co-infection with malaria is associated with less severe disease and early recovery in the form of early VC. Genetic and immunological studies are necessary to confirm malaria protection against SARS-CoV-2 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 infection | |
| 650 | 4 | |a co-infection | |
| 650 | 4 | |a dengue | |
| 650 | 4 | |a malaria | |
| 650 | 4 | |a vector-borne disease | |
| 700 | 1 | |a Mahajan, Niraj N |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Vartika |e verfasserin |4 aut | |
| 700 | 1 | |a Junare, Parmeshwar R |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Kaushal, Nandita |e verfasserin |4 aut | |
| 700 | 1 | |a Rathod, Darshana B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of vector borne diseases |d 2003 |g 60(2023), 2 vom: 01. Apr., Seite 211-214 |w (DE-627)NLM148104908 |x 0972-9062 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2023 |g number:2 |g day:01 |g month:04 |g pages:211-214 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/0972-9062.364758 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2023 |e 2 |b 01 |c 04 |h 211-214 | ||